Abstract: Objective To study the effect of Jieduliangxuefa in patients with chronic severe hepatitis B and to determine the opinion of the treatment crowd by using model for end-stage liver disease (MELD) scoring system.Methods 374 patients were randomly divided into Jieduliangxuefa group and control group, both the groups were treated with comprehensive physical treatment and MELD score was calculated according to the original formula for each patient.The efficacy of Jieduliangxuefa was assessed by mortality and improvement in biochemical parameters and MELD score.Results The levels of total bilirubin (TBil) , INR and MELD score of patients whose MELD scores were lower than 17 [TBil, (290.45±147.42) μmol/L;INR, 1.54±0.52;MELD, 11.87±2.04] were lower than those before Jieduliangxuefa treatment [TBil, (314.48±145.4) μmol/L;INR, 1.78±0.43;MELD, 13.81±1.78].The levels of TBil and INR and MELD score of patients whose MELD scores were higher than 17 [TBil, (401.38±139.27) μmol/L;INR, 3.30±1.44;MELD, 18.46±0.72] were higher than those before Jieduliangxuefa treatment [TBil, (398.86±121.82) μmol/L;INR, 3.15±1.6;MELD, 18.34±0.64].The mortality of patients in Jieduliangxuefa group with MELD score were lower than 17 was 14.4%, while it was 29.7% in control group, showing significant difference between Jieduliangxuefa group and control group (P<0.05) .The mortality of patients with MELD scores were higher than 17 was 31.3% in Jieduliangxuefa group and 35.3% in control group, showing no significant difference between the two groups (P>0.05) .Conclusion Jieduliangxuefa can decrease the serum TBil level, INR and MELD score of patients with fulminant hepatitis and improve liver function.Compare with the control group, Jieduliangxuefa can significantly decrease the mortality of patients in Jieduliangxuefa group with MELD score lower than 17, but no effect was observed in patients with MELD score higher than 17.